PSME3 promotes glycolysis and migration of gastric cancer cells via regulating the EGFR/c-myc pathway

Gastric cancer (GC) is a common malignant tumor that is pernicious to the health of patients. Proteasome activator subunit 3 (PSME3) has been shown to exhibit higher expression and aggravate tumorigenesis in cancer progression. A major finding is that PSME3 is also highly expressed in GC tissues, which results in a worse prognosis. Nevertheless, the regulatory functions of PSME3 in GC progression remain unclear. This study aimed to investigate the impacts of PSME3 and related regulatory pathways on GC progression. From the Gene Expression Profiling Interactive Analysis (GEPIA) database, it was noted that PSME3 expression was up-regulated in GC tissues. Our findings suggested that in GC, PSME3 showed higher expression, resulting in a worse prognosis. Functional experiments revealed that PSME3 accelerates cell growth, migration and abnormal glycolysis in GC. PSME3 stimulates the epidermal growth factor receptor (EGFR)/c-myc pathway. In conclusion, GC cells exhibited higher PSME3 expression, which modulated the EGFR/c-myc pathway to facilitate glycolysis and migration. PSME3 might be an effective bio-target for GC treatment.

PSME3; Glycolysis; Gastric cancer; EGFR/c-myc pathway

[1] Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiology, Biomarkers & Prevention. 2014; 23: 700–713.

[2] Wang Z, Han W, Xue F, Zhao Y, Wu P, Chen Y, et al. Nationwide gastric cancer prevention in China, 2021–2035: a decision analysis on effect, affordability and cost-effectiveness optimisation. Gut. 2022; 71: 2391–2400.

[3] Na H, Do HH, Lee SC, Lee JH, Seo JS, Kim YW, et al. Gastric point-of-care ultrasound evaluation in pediatric emergency department procedural sedation patients; is the stomach empty at the point of scheduled revisit? Signa Vitae. 2021; 17: 59–65.

[4] Kono Y, Kanzaki H, Iwamuro M, Kawano S, Kawahara Y, Okada H. Reality of gastric cancer in young patients: the importance and difficulty of the early diagnosis, prevention and treatment. Acta Medica Okayama. 2020; 74: 461–466.

[5] Li GZ, Doherty GM, Wang J. Surgical management of gastric cancer: a review. JAMA Surgery. 2022; 157: 446–454.

[6] Patel TH, Cecchini M. Targeted therapies in advanced gastric cancer. Current Treatment Options in Oncology. 2020; 21: 70.

[7] Mao I, Liu J, Li X, Luo H. REGgamma, a proteasome activator and beyond? Cellular and Molecular Life Sciences. 2008; 65: 3971–3980.

[8] Tanahashi N, Yokota K, Ahn JY, Chung CH, Fujiwara T, Takahashi E, et al. Molecular properties of the proteasome activator PA28 family proteins and gamma-interferon regulation. Genes to Cells. 1997; 2: 195–211.

[9] Song W, Guo C, Chen J, Duan S, Hu Y, Zou Y, et al. Silencing PSME3 induces colorectal cancer radiosensitivity by downregulating the expression of cyclin B1 and CKD1. Experimental Biology and Medicine. 2019; 244: 1409–1418.

[10] Yi Z, Yang D, Liao X, Guo F, Wang Y, Wang X. PSME3 induces epithelial–mesenchymal transition with inducing the expression of CSC markers and immunosuppression in breast cancer. Experimental Cell Research. 2017; 358: 87–93.

[11] Guo J, Hao J, Jiang H, Jin J, Wu H, Jin Z, et al. Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis. Cancer Letters. 2017; 386: 161–167.

[12] Chen ZM, Kai Z, Fang J, Chen Y, Fang YF, Hu SJ. The prognosis value of proteasome activator subunit 3 expression in gastric cancer. Journal of physiology and pharmacology. 2022; 73: 421–430.

[13] Wang F, Chen S, Peng S, Zhou X, Tang H, Liang H, et al. PRMT1 promotes the proliferation and metastasis of gastric cancer cells by recruiting MLXIP for the transcriptional activation of the β-catenin pathway. Genes & Diseases. 2023; 10: 2622–2638.

[14] Zeng Y, Zhang X, Li F, Wang Y, Wei M. AFF3 is a novel prognostic biomarker and a potential target for immunotherapy in gastric cancer. Journal of Clinical Laboratory Analysis. 2022; 36: e24437.

[15] Chen M, Wang G, Xu Z, Sun J, Liu B, Chang L, et al. Loss of RACK1 promotes glutamine addiction via activating AKT/mTOR/ASCT2 axis to facilitate tumor growth in gastric cancer. To be published in Cellular oncology. 2023. [Preprint].

[16] Li B, Han Y. NSD1 stimulated survival and migration of gastric cancer cells through WNT10B. Journal of Men’s Health. 2021; 17: 139–144.

[17] Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Molecular Cancer. 2013; 12: 152.

[18] Wang Z, Peng W, Zhang P, Yang X, Zhou Q. Lactate in the tumour microenvironment: from immune modulation to therapy. EBioMedicine. 2021; 73: 103627.

[19] Guo T, Bai Y, Cheng X, Han H, Du H, Hu Y, et al. Insulin gene enhancer protein 1 mediates glycolysis and tumorigenesis of gastric cancer through regulating glucose transporter 4. Cancer Communications. 2021; 41: 258–272.

[20] Cai Z, Zhang W, Zhou R, Wang Y, Feng Y. Protein phosphatase 2a inhibits gastric cancer cell glycolysis by reducing MYC signaling. Cell Biochemistry and Biophysics. 2023; 81: 59–68.

[21] Sun L, Li J, Yan W, Yao Z, Wang R, Zhou X, et al. H19 promotes aerobic glycolysis, proliferation, and immune escape of gastric cancer cells through the microRNA‐519d‐3p/lactate dehydrogenase A axis. Cancer Science. 2021; 112: 2245–2259.

[22] Wang M, Chen Y, Xu H, Zhan J, Suo D, Wang J, et al. HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer. Cancer Science. 2023; 114: 1365–1377.

[23] Zhao K, Wang Q, Wang Y, Huang K, Yang C, Li Y, et al. EGFR/c-myc axis regulates TGFβ/Hippo/Notch pathway via epigenetic silencing miR-524 in gliomas. Cancer Letters. 2017; 406: 12–21.

[24] Ko YC, Liu R, Sun HN, Yun BS, Choi HS, Lee DS. Dihydroconiferyl ferulate isolated from Dendropanax morbiferus H.Lév. suppresses stemness of breast cancer cells via nuclear EGFR/c-Myc signaling. Pharmaceuticals. 2022; 15: 664.